Clinical Trials · NCT01235741

A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects

Name: A Study To Examine The Efficacy And Safety Of Pramlintide+Metreleptin In Obese Subjects
Creator: Peptide Science Daily
License: https://clinicaltrials.gov/about-site/terms-conditions

TerminatedPhase 2Pramlintide

Phase: Phase 2
Recruitment status: Terminated
Sponsor: AstraZeneca
Enrollment: 213
Start date: Jan 2011
Locations: 18 sites, United States
Primary endpoint: Number of Participants With Treatment Emergent Adverse Events and Number With Post Treatment Adverse Events - Intent to Treat Population

View Pramlintide compound reference